NCT06461598View on ClinicalTrials.gov

Signature for Precise Chemosensitivity Prediction in PDAC

CompletedOBSERVATIONAL
Enrollment

365

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

May 31, 2021

Conditions
Pancreatic Cancer
Interventions
DRUG

Chemotherapy

All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).

Trial Locations (1)

200025

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06461598 - Signature for Precise Chemosensitivity Prediction in PDAC | Biotech Hunter | Biotech Hunter